Explain me everything about cushings syndrome

Reading File

Finding Sources

Searching PubMed

"Cushing syndrome" diagnosis management

Reading File

Loading Image

I now have comprehensive content from authoritative textbooks plus excellent diagrams. Here is the complete guide to Cushing's syndrome:

Cushing's Syndrome - A Complete Guide

1. Definition

Cushing's syndrome is the clinical state resulting from prolonged, inappropriate exposure of tissues to excess glucocorticoids - specifically cortisol. It is a rare condition, occurring in 2-5 per million people per year. When the cause is a pituitary ACTH-secreting tumor, the term Cushing's disease specifically applies. The broader term "Cushing's syndrome" covers all causes.

Campbell Walsh Wein Urology, p. 3134

2. Normal Physiology - The HPA Axis (Background)

The hypothalamic-pituitary-adrenal (HPA) axis is the governing feedback system:

The hypothalamus secretes corticotropin-releasing hormone (CRH), following circadian rhythms (peak cortisol in the morning, nadir ~11 PM)
CRH stimulates anterior pituitary corticotrophs to release ACTH (cleaved from pro-opiomelanocortin, POMC)
ACTH drives the zona fasciculata of the adrenal cortex to produce up to 20 mg of cortisol daily
Cortisol feeds back to the hypothalamus and pituitary to suppress further CRH and ACTH - completing the negative loop
Without ACTH, adrenal cortical cells (except mineralocorticoid-producing cells) undergo apoptosis
Campbell Walsh Wein Urology, p. 3134-3135

3. Classification and Causes

Causes of Cushing's Syndrome - Classification Flowchart

A. Exogenous (Iatrogenic) - MOST COMMON Overall

Administration of synthetic glucocorticoids (oral, topical, inhaled, nasal, injectable)
Even low doses can cause it; doses equivalent to ≥20 mg prednisone daily for >1 month are particularly risky
Patients may be unaware (herbal preparations, nasal sprays) or use steroids surreptitiously

B. Endogenous - ACTH-Dependent (80-85% of endogenous cases)

Cause	Frequency	Notes
Cushing's Disease (pituitary corticotroph adenoma)	~70% of endogenous	Usually a microadenoma; macroadenomas only ~5%; 2/3 female
Ectopic ACTH syndrome	~10-15%	Caused by non-pituitary malignant tumors (small cell lung cancer, carcinoids, pancreatic islet tumors, medullary thyroid cancer); very high ACTH levels
Ectopic CRH syndrome	<1%	Extremely uncommon

C. Endogenous - ACTH-Independent (~15-20% of endogenous)

Cause	Frequency	Notes
Adrenal adenoma	~10%	Benign, unilateral; most common ACTH-independent cause
Adrenocortical carcinoma (ACC)	~8%	Independent predictor of poor outcome
ACTH-independent macronodular adrenal hyperplasia (AIMAH)	<1%	Large bilateral nodules, each gland >60 g
Primary Pigmented Nodular Adrenocortical Disease (PPNAD)	<1%	Normal-sized glands with black/brown nodules; associated with Carney complex (autosomal dominant)

Campbell Walsh Wein Urology, pp. 3135-3136

4. Clinical Features

Multi-system effects of hypercortisolism

Body Habitus & Fat Distribution

Central obesity - face, neck, trunk, abdomen - with sparing of the limbs
Moon face - round, wide, plethoric
Buffalo hump - dorsal cervical fat pad
Supraclavicular fat pads

Skin Changes (highly characteristic)

Violaceous (purple) striae - wide (>1 cm), atrophic; abdomen, flanks, breasts, thighs
Skin thinning and fragility - "cigarette paper" wrinkling, easy peeling after adhesive tape (Liddle sign)
Easy bruising - ecchymoses without trauma
Plethora - reddish facial flush
Hypertrichosis / facial lanugo hair (especially in women)
Acne
Susceptibility to superficial fungal infections (dermatophytes, Pityrosporum)

Musculoskeletal

Proximal muscle weakness - difficulty rising from a chair, climbing stairs
Osteoporosis - kyphosis, vertebral fractures, back pain
Bone loss begins early in the course

Metabolic

Hypertension (75-80%) - multiple mechanisms: sodium/water retention, increased vascular reactivity, RAAS activation
Diabetes mellitus / insulin resistance (18-30%)
Dyslipidemia
Central obesity / metabolic syndrome

Neuropsychiatric

Depression - most common psychiatric feature
Anxiety, emotional lability, cognitive impairment
Psychosis (less common but serious)

Reproductive / Endocrine

Hypogonadism - loss of libido, impotence, menstrual irregularities, amenorrhea
Decreased axillary/pubic hair
Clitoromegaly (in women, from androgen excess)

Cardiovascular

Ventricular hypertrophy, cardiac fibrosis
Prothrombotic state - DVT, pulmonary embolism (major cause of death)

Other

Glaucoma, cataracts
Peptic ulcer disease
Urolithiasis (hypercalciuria)
Immunosuppression - increased infection risk
Impaired wound healing
Fitzpatrick's Dermatology, p. 578 | Campbell Walsh Wein Urology, pp. 3136-3138 | Braunwald's Heart Disease, p. 1141

5. Pseudo-Cushing's Syndrome

Certain conditions can mimic Cushing's syndrome biochemically and clinically, but do not represent true pathological hypercortisolism:

Alcohol dependence
Morbid obesity
Poorly controlled diabetes mellitus
Glucocorticoid resistance
Major depression

These states are particularly difficult to distinguish from true Cushing's and may require specialized testing.

Campbell Walsh Wein Urology, p. 3138

6. Diagnosis

Diagnosis is a two-step process: (1) confirm hypercortisolism, then (2) identify the cause.

Step 1: Confirm Cushing's Syndrome

Diagnostic algorithm for adrenal mass with suspected Cushing's

First, exclude exogenous glucocorticoid use (careful drug history). Then perform one or more of:

Test	Details	Cut-off/Notes
Overnight 1 mg dexamethasone suppression test (DST)	1 mg dexamethasone at 11 PM; plasma cortisol at 8 AM	Cortisol <50 nmol/L = normal (rules out Cushing's)
24-hour urinary free cortisol (UFC)	≥2 collections recommended	≥3x upper limit of normal = 95-100% sensitive and specific
Late-night salivary cortisol	≥2 samples recommended	Exploits the lost circadian nadir; highly sensitive
Low-dose DST (2 mg/48 hrs)	More thorough confirmation	Used when overnight DST equivocal

Repeat testing is prudent when any single result is positive. Late-night plasma cortisol >207 nmol/L is also highly suggestive.

Step 2: Identify the Cause - Localization

Measure serum ACTH:

Low ACTH (<10 pg/mL) → ACTH-independent → adrenal imaging (CT/MRI of adrenals)
- Normal adrenals → suspect exogenous steroids or PPNAD (check for paradoxical cortisol rise on DST)
- Bilateral lesions → consider adrenal venous sampling (AVS)
High ACTH (>20 pg/mL) → ACTH-dependent → need to distinguish pituitary vs. ectopic

Distinguishing pituitary from ectopic ACTH:

MRI of the pituitary (gadolinium-enhanced) - microadenomas found in only ~50% of Cushing's disease
High-dose DST (8 mg overnight): Cushing's disease typically suppresses; ectopic ACTH syndrome does NOT suppress
CRH stimulation test: pituitary adenomas respond with ACTH/cortisol rise; ectopic tumors typically do not
Inferior petrosal sinus sampling (IPSS) - gold standard for distinguishing pituitary from ectopic; requires expertise at specialized centers
CT chest/abdomen for ectopic tumors
Campbell Walsh Wein Urology, pp. 3138-3142 | Andrews' Diseases of the Skin, p. 3834 | Fitzpatrick's Dermatology, p. 578

7. Management

A. Surgery - First-Line

Cushing's Disease (pituitary):

Transsphenoidal surgery (TSS) - treatment of choice; remission rates 65-90% for microadenomas, lower for macroadenomas
If pituitary adenoma cannot be found or resected, bilateral adrenalectomy is an option
Radiation (stereotactic radiosurgery / conventional) as adjunct or second-line

ACTH-Independent adrenal causes:

Adrenalectomy - laparoscopic preferred for unilateral disease
Bilateral adrenalectomy for bilateral disease (AIMAH, PPNAD)
Cushingoid phenotype resolves in 7-9 months post-adrenalectomy; may persist years in some

Ectopic ACTH:

Resect primary tumor if possible
Bilateral adrenalectomy if tumor not resectable

B. Perioperative Management (especially adrenalectomy)

Pre-operative:

Metyrapone to block cortisol production when severe symptoms (hypertension, DM, hypokalemia, myopathy)
Correct hypertension and hyperglycemia
VTE prophylaxis (high thrombotic risk)
Preoperative antibiotics
Stress-dose steroid administration intraoperatively

Post-operative:

Replacement glucocorticoids mandatory (the contralateral/remaining adrenal is suppressed and requires time to recover)
Monitor for adrenal insufficiency
Bone mineral density (BMD) improves after resolution - recent meta-analysis (PMID: 39689783) confirms significant BMD recovery post-cure

C. Medical Therapy

Used as bridge to surgery, or when surgery is not possible:

Drug	Mechanism	Notes
Metyrapone	11β-hydroxylase inhibitor; blocks cortisol synthesis	Rapid onset; most commonly used
Ketoconazole	Multiple steroidogenesis enzymes; blocks cortisol and androgen synthesis	Risk of hepatotoxicity
Mitotane	Adrenolytic; used for adrenocortical carcinoma	Slow onset; toxic
Osilodrostat	11β-hydroxylase inhibitor	Newer agent
Mifepristone	Glucocorticoid receptor antagonist	Useful when surgical cure not possible
Pasireotide	Somatostatin receptor agonist → reduces ACTH from pituitary	For Cushing's disease
Cabergoline	Dopamine agonist	Some response in Cushing's disease

D. Radiation

Stereotactic radiosurgery (Gamma Knife) for residual/recurrent pituitary tumors
Conventional fractionated radiation as alternative
Onset of effect is delayed (months to years)
Campbell Walsh Wein Urology, pp. 3142-3150 | Braunwald's Heart Disease, p. 1141

8. Prognosis and Complications

Untreated Cushing's syndrome carries significantly elevated mortality, primarily from cardiovascular events and infections
Venous thromboembolism is a major cause of death; prophylaxis is essential
Cardiovascular risk persists even after cure - cardiac structural changes can take years to reverse
Bone density recovers after successful treatment, though may not fully normalize
Psychiatric symptoms often persist or take months to resolve post-cure
Nelson's syndrome: after bilateral adrenalectomy for Cushing's disease, the underlying pituitary tumor can expand aggressively due to loss of cortisol feedback, causing hyperpigmentation and mass effects
Braunwald's Heart Disease, pp. 1141-1142 | Campbell Walsh Wein Urology, p. 3150

9. Special Situations

Subclinical Cushing's syndrome: Biochemical evidence of hypercortisolism without the full clinical picture; discovered incidentally on adrenal imaging. Management is debated - surgery vs. watchful waiting. A 2024 meta-analysis (PMID: 39086899) examined surgical vs. conservative approaches for mild autonomous cortisol secretion.

Cyclic Cushing's: Intermittent hypercortisolism making diagnosis elusive; multiple UFC measurements improve detection.

Pediatric Cushing's: Growth retardation is an early sign; adrenal carcinoma is relatively more common than in adults.

MEN1 / Carney Complex: Cushing's syndrome occurs as part of hereditary syndromes and should prompt genetic evaluation.

Summary Table

Feature	Details
Definition	Prolonged excess glucocorticoid exposure
Most common cause	Exogenous steroids (iatrogenic)
Most common endogenous cause	Cushing's disease (pituitary microadenoma)
Female:male ratio	~4:1 (non-iatrogenic)
Key classic signs	Central obesity, moon facies, buffalo hump, purple striae, easy bruising, proximal myopathy
First-line screening test	Overnight 1 mg DST + 24-hr UFC
Distinguish ACTH-dep vs. indep	Serum ACTH level
Best test pituitary vs. ectopic	Inferior petrosal sinus sampling (IPSS)
First-line treatment	Surgery (transsphenoidal or adrenalectomy depending on cause)
Main cause of death	VTE and cardiovascular disease

Sources: Campbell Walsh Wein Urology, 3e | Fitzpatrick's Dermatology | Andrews' Diseases of the Skin | Braunwald's Heart Disease | PubMed (PMIDs 39086899, 39689783)

This is a shared conversation. Sign in to Orris to start your own chat.